Drospirenone/estetrol monohydrate (Drovelis®). HTA ID: 22073
Drospirenone/estetrol monohydrate is indicated for oral contraception.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 07/12/2022 |
| Rapid review completed | 23/01/2023 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that drospirenone/estetrol monohydrate not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.